Dayvigo Tablet, Film Coated
Product Images NDC 62856-410

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Dayvigo (NDC 62856-410). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eisai Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Structural Formula For Dayvigo Contains Lemborexant, An Orexin Receptor Antagonist. The Chemical Name Of Lemborexant Is (1r,2s)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-n-(5-fluoropyridin-2-yl) Cyclopropanecarboxamide. The Molecular Formula Is C22h20f2n4o2. The Molecular Weight Is 410.42. (Dayvigo 01)

Chemical structure of the active ingredient in DAYVIGO, showing a complex molecule with multiple rings, fluorine atoms, and nitrogen atoms.*

FDA Label Image

Figure 1. Effects Of Hepatic And Renal Impairment On Lemborexant Pharmacokinetics (Dayvigo 02)

A chart titled 'Fold Change and 90% Confidence Intervals' showing the change relative to reference for Cmax and AUC in conditions of hepatic impairment (moderate and mild) and severe renal impairment. The chart includes confidence intervals for each measurement comparing impaired to normal function.*

FDA Label Image

Figure 2. Effects Of Co-administered Drugs On The Pharmacokinetics Of Lemborexant 10 mg (Dayvigo 03)

A chart displaying fold changes and 90% confidence intervals for various interacting drugs on DAYVIGO, comparing C_max and AUC values relative to a reference. Interacting drugs include Rifampin (strong CYP3A inducer), Itraconazole (strong CYP3A inhibitor), Fluconazole (moderate CYP3A inhibitor), Alcohol, Famotidine (gastric pH modifier), and oral contraceptives (Ethinyl Estradiol + Norethindrone). The horizontal axis shows fold change relative to reference ranging from 0 to 5.*

FDA Label Image

Figure 3. Effects Of Lemborexant 10 mg On The Pharmacokinetics Of Co-administered Drugs (Dayvigo 04)

A horizontal dot plot with 90% confidence intervals showing the fold change in Cmax and AUC for various interacting drugs relative to a reference. The drugs listed are CYP2B6 substrates S-Bupropion and [S,S]-Hydroxylated Bupropion, CYP3A substrate Midazolam, and oral contraceptives Ethinyl Estradiol and Norethindrone. The x-axis measures change relative to reference from 0.0 to 2.0, depicting the degree of interaction effect on drug exposure.*

FDA Label Image

Principal Display Panelndc 62856-405-30dayvigo(lemborexant) Tablets5 mg30 Tablets (Dayvigo 05)

Label for DAYVIGO (lemborexant) tablets showing 5 mg strength in a package of 30 tablets. The label includes dosage form text, storage instructions, and a dispensing notice. It states the labeler as Eisai Inc., Nutley, NJ, with manufacturing in Japan. The label also displays an NDC number and barcode.*

FDA Label Image

Principal Display Panelndc 62856-405-90dayvigo(lemborexant) Tablets5 mg90 Tablets (Dayvigo 06)

Packaging label for DAYVIGO (lemborexant) tablets, 5 mg strength, containing 90 tablets. The label includes storage instructions, manufacturer information (Eisai Inc., Woodcliff Lake, NJ, made in Japan), and notes it is a prescription-only product with a dispenser medication guide requirement. The National Drug Code (NDC) is 62856-405-90.*

FDA Label Image

Principal Display Panelndc 62856-410-30dayvigo(lemborexant) Tablets10 mg30 Tablets (Dayvigo 07)

DAYVIGO (lemborexant) tablets 10 mg carton label by Eisai Inc. The label indicates a 30-tablet package with NDC 62856-410-30. It includes storage instructions, patient dispensing guidance, and notes the product is made in Japan. The label also features barcode and handling information such as "Bottle Corner" and "No Varnish."*

FDA Label Image

Principal Display Panelndc 62856-410-90dayvigo(lemborexant) Tablets10 mg90 Tablets (Dayvigo 08)

DAYVIGO 10 mg (lemborexant) tablets packaging label for 90 tablets. The label displays the proprietary name DAYVIGO with the active ingredient lemborexant, strength 10 mg, and quantity of 90 tablets. It includes storage instructions, a note on accompanying Medication Guide, and distributor Eisai Inc., Woodcliff Lake, NJ. Made in Japan.*

FDA Label Image

Dayvigo 09

DAYVIGO 5 mg tablets packaging label showing the brand name with active ingredient lemborexant. The label includes instructions to push tablet through foil and features a 10-day calendar layout with circles labeled from Day 1 to Day 10. The label indicates the tablets are for prescription use only and are a professional sample not for sale. Distributed by Eisai Inc., Nutley, NJ, made in Japan.*

FDA Label Image

Dayvigo 0a

DAYVIGO 5 mg (lemborexant) tablets packaging label in white and blue. The label displays the product name, active ingredient lemborexant, strength 5 mg, and indicates professional sample not for sale or re-sale. It includes manufacturer Eisai Inc. and dosage form as tablets. The label also has NDC number, usage and storage instructions, and warnings about dispensing with the medication guide.*

FDA Label Image

Dayvigo 0b

Packaging label for DAYVIGO 5 mg tablets by Eisai Inc. The label shows the proprietary name DAYVIGO, the active ingredient lemborexant, strength of 5 mg, and indicates the product is prescription only (Rx only). It includes storage instructions and states the package contains 5 cartons, each with one blister card of 10 tablets. The label also notes that an accompanying Medication Guide is provided inside each carton.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.